In the race to get critically needed drugs to market, every study sponsor/CRO, globally, seeks to arrive to Day 1, Patient 1 as quickly as possible, without sacrificing the robust study and budget design necessary for a fair and site-championed clinical trial agreement.
Budget design and negotiation is a complex process in and of itself. It needs to account for both sponsor/CRO and site requirements and expenditures, and also reflect the local fair market value for its constituent costs and line-items.
This paper seeks to explore the most crucial obstacles to successful budget design and negotiation in light of the current complexity experienced across the clinical trial universe. It highlights how technology can streamline these traditionally manual, time-consuming workflows, increase transparency and predictability, and deliver more current, and accurate data for an optimized study start-up.